Brokerages Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $137.15

Abivax SA Sponsored ADR (NASDAQ:ABVX) has been assigned an average rating of “Moderate Buy” from the fourteen brokerages that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month target price among brokerages that have covered the stock in the last year is $137.1538.

Several research firms have recently commented on ABVX. Jefferies Financial Group assumed coverage on Abivax in a research report on Monday, March 16th. They issued a “buy” rating and a $160.00 target price on the stock. Piper Sandler restated an “overweight” rating and issued a $142.00 price target on shares of Abivax in a research note on Tuesday, December 16th. Weiss Ratings restated a “sell (d-)” rating on shares of Abivax in a research note on Wednesday, January 21st. Oppenheimer set a $131.00 target price on shares of Abivax in a research report on Thursday, January 8th. Finally, Wedbush initiated coverage on shares of Abivax in a report on Tuesday, February 24th. They set an “outperform” rating and a $110.00 target price on the stock.

Institutional Trading of Abivax

Several large investors have recently modified their holdings of ABVX. Jefferies Financial Group Inc. acquired a new stake in Abivax during the third quarter worth about $38,827,000. Kennedy Capital Management LLC raised its position in shares of Abivax by 7.1% in the 2nd quarter. Kennedy Capital Management LLC now owns 241,188 shares of the company’s stock valued at $1,845,000 after buying an additional 15,997 shares in the last quarter. Federated Hermes Inc. bought a new stake in shares of Abivax during the 3rd quarter worth approximately $8,448,000. Persistent Asset Partners Ltd bought a new stake in shares of Abivax during the 3rd quarter worth approximately $815,000. Finally, Atika Capital Management LLC acquired a new stake in shares of Abivax during the 3rd quarter worth approximately $5,858,000. 47.91% of the stock is owned by institutional investors and hedge funds.

Abivax Stock Performance

Shares of ABVX stock opened at $118.37 on Monday. Abivax has a 52 week low of $4.77 and a 52 week high of $148.83. The company has a market capitalization of $9.37 billion, a price-to-earnings ratio of -22.04 and a beta of 1.68. The company has a 50-day simple moving average of $117.64 and a 200 day simple moving average of $112.34.

Abivax (NASDAQ:ABVX) last released its quarterly earnings results on Saturday, February 14th. The company reported ($1.20) earnings per share for the quarter. The business had revenue of $0.52 million for the quarter. Sell-side analysts forecast that Abivax will post -2.83 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.